Hillstream’s New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing at EORTC-NCI-AACR Symposium
October 18 2022 - 8:47AM
Hillstream BioPharma, Inc. (“Hillstream”), a biotechnology company
developing novel therapeutic candidates targeting ferroptosis, an
emerging new anti-cancer mechanism resulting in iron mediated cell
death for drug resistant and devastating cancers, today announced
that an abstract highlighting the progress of the Quatramer-based
Ferroptosis Inducer, HSB-1216, are available as a poster at the
34th EORTC- NCI - AACR Symposium (ENA 2022) in Barcelona taking
place from October 26 -28, 2022.
AML is characterized by the unbridled proliferation of myeloid
progenitor cells. Unfortunately, despite recent advances in the
treatment, the prognosis is poor for almost all older adults and
half of patients under age 60. Leukemic stem cells (LSCs) represent
a subset of the leukemic cell population contributing to leukemia
relapse and are relatively refractory to conventional treatments.
HSB-1216 treatment resulted in growth inhibition and induction of
cell death of multiple AML cell lines. Additionally, Midostaurin
(FLT-3 and pan kinase inhibitor)- resistant and
Venetoclax-resistant AML cells are sensitive to HSB-1216-induced
growth arrest. “The accepted abstract summarizes non-clinical
findings using HSB-1216 as a single agent and in combination with
decitabine in acute myeloid leukemia (AML), a significant unmet
need” stated Randy Milby, CEO of Hillstream BioPharma. “In
addition, we are actively evaluating the potential utility of
HSB-1216 in a variety of solid tumor types.”
The poster website will be available two weeks prior to the
meeting.
Abstract Number 141: Novel iron mediated cell death
(ferroptosis) inducer HSB-1216; suppress acute myeloid leukemia
growth
- Session Type: Poster
- Session Category: Apoptosis inducers
- Session Title: Novel iron mediated cell death (ferroptosis)
inducer HSB-1216, suppress acute myeloid leukemia growth
The abstract will be published online on the ENA 2022 website (
https://event.eortc.org/ena2022) two weeks before the meeting, and
will be accessible on the Hillstream website
(www.hillstreambio.com).
About HSB-1216HSB-1216 is a novel and potent
inducer of an emerging mechanism of cell death called
ferroptosis. This process allows HSB-1216 to cause lysosomal
membrane permeabilization of hard-to-treat cancer cells – causing
them to rupture and stop replicating. The development of
HSB-1216 is focused on a variety of solid tumors with high unmet
need. HSB-1216 leverages the Quatramer platform, a
tumor-targeted platform with capacity to deliver drug and biologic
combinations to solid tumors. Quatramer enhances the uptake of
HSB-1216 in the tumor microenvironment with an extended duration of
action and minimal off-target toxicity. Quatramer offers the
potential to significantly improve the profile and widen the
therapeutic window of HSB-1216 and other small molecules, peptides,
cytokines and oligomers preferentially delivered to tumors.
Quatramer building blocks are pH-triggered to degrade
intra-cellularly.
About Hillstream BioPharma Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing novel
therapeutic candidates targeting ferroptosis, an emerging new
anti-cancer mechanism resulting in iron mediated cell death for
drug resistant and devastating cancers. Hillstream’s most advanced
candidate is HSB-1216, an IMCD modulator, targeting a variety of
solid tumors. The active drug in HSB-1216 was found to be
efficacious in a clinical pilot study in Germany in devastating
cancers, including triple negative breast cancer and epithelial
carcinomas. Hillstream intends to initiate IND discussions with the
FDA in first half of 2023. Hillstream uses Quatramer™, our
proprietary tumor targeting platform, to enhance the uptake of
HSB-1216 in the tumor microenvironment with an extended duration of
action and minimal off-target toxicity. For more information,
please visit:www.hillstreambio.com
Hillstream BioPharma Inc.
Investor Contact: investorrelations@hillstreambio.com
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Apr 2023 to Apr 2024